Who is sponsoring NCT05495503?

NCT05495503 is sponsored by Cryonove Pharma.

What drugs are being tested in NCT05495503?

Interventions in NCT05495503: Prototype (814A-v1), Prototype (814B-v1), Prototype (814C-v1), Prototype (814D-v1).

What condition does NCT05495503 study?

NCT05495503 studies Post-inflammatory Hyperpigmentation.

Is NCT05495503 still recruiting?

NCT05495503 is currently completed. Last updated 26 June 2023.

Last reviewed 2023-06-26 · How we verify

NCT05495503

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Post-inflamamatory Hyperpigmentation (PIH).

Completed NA Last updated 26 June 2023

What this trial tests

NA trial testing Prototype (814A-v1) in Post-inflammatory Hyperpigmentation in 12 participants. Completed in 14 December 2022.

Timeline

18 October 2022

Primary endpoint
14 December 2022

14 December 2022

Quick facts

Lead sponsor	Cryonove Pharma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	12
Start date	18 October 2022
Primary completion	14 December 2022
Estimated completion	14 December 2022
Sites	1 location across South Africa

Drugs / interventions tested

Prototype (814A-v1)
Prototype (814B-v1)
Prototype (814C-v1)
Prototype (814D-v1)

Conditions studied

Post-inflammatory Hyperpigmentation — all drugs for Post-inflammatory Hyperpigmentation →

Sponsor

Cryonove Pharma

Who can join

Adults 18 to 65, any sex, with Post-inflammatory Hyperpigmentation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CS5\_2 study aims to evaluate the tolerance of 4 different conditions of cryotherapy treatments applied on dorsal post-inflammatory hyperpigmentation (PIH) spots. This study is a proof of concept, designed to be interventional, monocentric, randomized and double blind. The study will evaluate 4 prototypes : (814A-v1), (814B-v1), (814C-v1) and (814D-v1).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cryonove Pharma trials

Trials by the same sponsor.

NCT06361251 — Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyt · NA · completed
NCT05886010 — Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and S · NA · unknown
NCT05883657 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and · NA · unknown
NCT05625815 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots. · NA · completed
NCT05793619 — Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment o · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05495503 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cryonove Pharma
Last refreshed: 26 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing